Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer

Nivolumab is an immune checkpoint inhibitor with demonstrated efficacy against several malignant tumors. Alterations in driver oncogenes such as EGFR and ALK are a poor prognostic factor in nivolumab therapy for non-small cell lung cancer (NSCLC), whereas a smoking history is a well-known, favorable...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Masahiro, Saito, Naomi, Hada, Yu, Miyamoto, Sayaka, Okanobu, Hideharu, Ikeda, Naoya, Daido, Wakako, Ishiyama, Sayaka, Deguchi, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436064/
https://www.ncbi.nlm.nih.gov/pubmed/28559820
http://dx.doi.org/10.1159/000470830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436064/
https://www.ncbi.nlm.nih.gov/pubmed/28559820
http://dx.doi.org/10.1159/000470830

Ejemplares similares